Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1986 1
1988 1
1989 4
1990 20
1991 10
1992 13
1993 5
1994 13
1995 4
1996 6
1997 6
1998 7
1999 4
2000 13
2001 5
2002 12
2003 15
2004 12
2005 10
2006 10
2007 12
2008 10
2009 16
2010 16
2011 15
2012 15
2013 11
2014 17
2015 21
2016 16
2017 19
2018 23
2019 14
2020 24
2021 17
2022 13
2023 14
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

412 results

Results by year

Filters applied: . Clear all
Page 1
BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.
Kurata K, Samur MK, Liow P, Wen K, Yamamoto L, Liu J, Morelli E, Gulla A, Tai YT, Qi J, Hideshima T, Anderson KC. Kurata K, et al. Among authors: tai yt. Clin Cancer Res. 2023 May 1;29(9):1807-1821. doi: 10.1158/1078-0432.CCR-22-3668. Clin Cancer Res. 2023. PMID: 36780189 Free PMC article.
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC. Gulla A, et al. Among authors: tai yt. Blood Cancer Discov. 2021 Sep;2(5):468-483. doi: 10.1158/2643-3230.BCD-21-0047. Epub 2021 Apr 23. Blood Cancer Discov. 2021. PMID: 34568832 Free PMC article.
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti M, Munshi NC, Wu H, Carrasco RD, Chauhan D, Anderson KC. Du T, et al. Among authors: tai yt. Blood. 2023 May 25;141(21):2599-2614. doi: 10.1182/blood.2022017897. Blood. 2023. PMID: 36630605
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW. de Weers M, et al. Among authors: tai yt. J Immunol. 2011 Feb 1;186(3):1840-8. doi: 10.4049/jimmunol.1003032. Epub 2010 Dec 27. J Immunol. 2011. PMID: 21187443 Clinical Trial.
Targeting CD38 alleviates tumor-induced immunosuppression.
Tai YT, Anderson KC. Tai YT, et al. Oncotarget. 2017 Dec 26;8(68):112166-112167. doi: 10.18632/oncotarget.22992. eCollection 2017 Dec 22. Oncotarget. 2017. PMID: 29348814 Free PMC article. No abstract available.
Immunotherapeutic and Targeted Approaches in Multiple Myeloma.
Nadeem O, Tai YT, Anderson KC. Nadeem O, et al. Among authors: tai yt. Immunotargets Ther. 2020 Oct 14;9:201-215. doi: 10.2147/ITT.S240886. eCollection 2020. Immunotargets Ther. 2020. PMID: 33117743 Free PMC article. Review.
412 results